title: Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
authors.affiliation: Division of Oncology, University of Washington, Seattle.
authors.forename: M C
authors.initials: MC
authors.lastname: Benyunes
authors.forename: J A
authors.initials: JA
authors.lastname: Thompson
authors.forename: A
authors.initials: A
authors.lastname: York
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: A
authors.initials: A
authors.lastname: Fefer
mesh_terms: D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007938:Leukemia / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D014182:Transplantation, Autologous
chemical_list: D007376:Interleukin-2